This article is more than 5 years old. Information may no longer be current.
No significant differences in AE rate observed between extramedullary, intramedullary implants
Click Here to Manage Email Alerts
Researchers found no significant difference in the rate of adverse events following intertrochanteric fracture treatment with either extramedullary or intramedullary implant, according to the results of a recently published study.
The researchers retrospectively culled information from the American College of Surgeons National Surgical Quality Improvement Program database for 4,432 patients older than 70 years who were treated with either extramedullary (36.4%) or intramedullary (63.6%) implants for an intertrochanteric fracture between 2009 and 2012. The primary metric of study was a comparison of patient outcomes, adjusted for demographics and comorbidities, between both implant types.
Patients in the intramedullary implant cohort were found to have a shorter mean postoperative length of hospital stay than those in the extramedullary group (5.4 days vs. 6.5 days, respectively). The researchers found no significant differences between the implant types with regard to the rates of adverse events, serious adverse events or readmission rates. Additionally, operating and OR times did not significantly vary between implant cohorts.
Disclosure: Grauer reports personal fees from legal case reviews, Affinergy, Alphatec, Bioventus, Depuy, Harvard Clinical Research Institute, Powered Research, Stryker and Transgenomic; grants and personal fees from Smith & Nephew, and personal fees from Medtronic and KCI outside the submitted work. Golinvaux reports grants from Doris Duke Clinical Research Fellowship during the conduct of the study. Baumgaertner reports personal fees from AONA and AO Foundation outside the submitted work. Basques reports grants from National Institutes of Health during the conduct of the study.
Click Here to Manage Email Alerts